Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from China Isotope & Radiation Corp. ( (HK:1763) ) is now available.
China Isotope & Radiation Corporation has scheduled a board meeting on 27 March 2026 to review and approve its annual results for the financial year ended 31 December 2025. The board will also consider recommending a final dividend, signaling the company is moving ahead with its regular governance and shareholder return processes for the past year.
The announcement also confirms the current composition of the board, detailing its executive, non-executive and independent non-executive directors. This underscores the firm’s established corporate governance framework as it prepares to finalize 2025 financial disclosures and potential dividend decisions that will be closely watched by investors.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$26.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
More about China Isotope & Radiation Corp.
China Isotope & Radiation Corporation is a mainland China-based company engaged in the isotope and radiation sector, operating through a network of subsidiaries. Listed in Hong Kong, it focuses on producing and supplying nuclear-related products and services, positioning itself within the broader medical and industrial radiation markets.
Average Trading Volume: 191,661
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.67B
See more data about 1763 stock on TipRanks’ Stock Analysis page.